Avelumab Recommended for EU Approval for Merkel Cell Carcinoma

July 21, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of avelumab for adults with metastatic Merkel cell carcinoma, according to Pfizer and Merck, the codevelopers of the PD-L1 inhibitor. The European Commission is expected to rule on the application later this year. If approved, avelumab would be the first immunotherapy treatment indicated for metastatic Merkel … (leggi tutto)